China-based Luye Pharma’s (SEHK: 2186) pipeline asset LY03010, a once-monthly, long-acting injectable (LAI) form of paliperidone, has achieved the primary endpoint in a pivotal trial and demonstrated comparable bioavailability with Johnson & Johnson’s (NYSE: JNJ) Invega Sustenna (1-month paliperidone palmitate) at steady state.
If approved, it will create more options for the management of schizophrenia, but will have to face a crowded LAI market, says data and analytics company GlobalData.
According to GlobalData’s report, “ Schizophrenia Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031,” LY03010 is anticipated to be launched in the USA in second-quarter 2024. It is forecast to reach sales of $63.5 million in 2031, representing 0.6% of the US schizophrenia market in 2031.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze